Miranda G Law1, Stephanie Komura1, Ann P Murchison2, Laura T Pizzi3. 1. Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA. 2. Codirector, Emergency Department, and Associate Professor of Ophthalmology, Wills Eye Hospital, Philadelphia, PA. 3. Associate Professor, Department of Pharmacy Practice, Jefferson School of Pharmacy, Thomas Jefferson University.
Abstract
BACKGROUND: Diabetic retinopathy is a retinal vascular disorder that affects more than 4.1 million people in the United States. New methods of detecting and ensuring adequate follow-up of this life-altering disease are vital to improving patient outcomes. Wills Eye Hospital and the Centers for Disease Control and Prevention are conducting a collaborative study to initiate a novel diabetic retinopathy screening in the community setting. OBJECTIVE: To evaluate the feasibility of a more widespread, large-scale implementation of this novel model of care for diabetic retinopathy screening in the community setting. METHODS: A simple, self-administered survey was distributed to pharmacists, pharmacy technicians, student pharmacists, and Wills Eye Hospital interns. The survey consisted of open-ended questions and responders were given 1 week to respond. A total of 22 surveys were distributed and 16 were completed. The responses were culled and analyzed to assess the feasibility of implementing this novel screening model in the pharmacy. RESULTS: The response rate to this pilot survey was 72%. The majority of the responding pharmacy staff members indicated that diabetic retinopathy screening in community pharmacies would greatly benefit patients and could improve patient care. However, they also noted barriers to implementing the screening, such as concerns about the cost of carrying out the screenings, the cost of the equipment needed to be purchased, and the lack of time and shortage of pharmacy staff. CONCLUSION: The potential exists for pharmacists to positively influence diabetes care by implementing retinopathy care through the early detection of the disease and reinforcement of the need for follow-up; however, real-world barriers must be addressed before widespread adoption of such a novel model of care becomes feasible.
BACKGROUND:Diabetic retinopathy is a retinal vascular disorder that affects more than 4.1 million people in the United States. New methods of detecting and ensuring adequate follow-up of this life-altering disease are vital to improving patient outcomes. Wills Eye Hospital and the Centers for Disease Control and Prevention are conducting a collaborative study to initiate a novel diabetic retinopathy screening in the community setting. OBJECTIVE: To evaluate the feasibility of a more widespread, large-scale implementation of this novel model of care for diabetic retinopathy screening in the community setting. METHODS: A simple, self-administered survey was distributed to pharmacists, pharmacy technicians, student pharmacists, and Wills Eye Hospital interns. The survey consisted of open-ended questions and responders were given 1 week to respond. A total of 22 surveys were distributed and 16 were completed. The responses were culled and analyzed to assess the feasibility of implementing this novel screening model in the pharmacy. RESULTS: The response rate to this pilot survey was 72%. The majority of the responding pharmacy staff members indicated that diabetic retinopathy screening in community pharmacies would greatly benefit patients and could improve patient care. However, they also noted barriers to implementing the screening, such as concerns about the cost of carrying out the screenings, the cost of the equipment needed to be purchased, and the lack of time and shortage of pharmacy staff. CONCLUSION: The potential exists for pharmacists to positively influence diabetes care by implementing retinopathy care through the early detection of the disease and reinforcement of the need for follow-up; however, real-world barriers must be addressed before widespread adoption of such a novel model of care becomes feasible.
Authors: Leah Fuller; Wayne F Conrad; Pamela C Heaton; Ralph Panos; William Eschenbacher; Stacey M Frede Journal: J Am Pharm Assoc (2003) Date: 2012 Sep-Oct
Authors: Cameron Winfrey; Sara Wortman; Stacey Frede; Natalie Kunze; Wayne F Conrad; Pamela C Heaton Journal: J Am Pharm Assoc (2003) Date: 2011 May-Jun
Authors: J P Boyle; A A Honeycutt; K M Narayan; T J Hoerger; L S Geiss; H Chen; T J Thompson Journal: Diabetes Care Date: 2001-11 Impact factor: 19.112
Authors: John H Kempen; Benita J O'Colmain; M Cristina Leske; Steven M Haffner; Ronald Klein; Scot E Moss; Hugh R Taylor; Richard F Hamman Journal: Arch Ophthalmol Date: 2004-04
Authors: Nicole Lowres; Ines Krass; Lis Neubeck; Julie Redfern; Andrew J McLachlan; Alexandra A Bennett; S Ben Freedman Journal: Int J Clin Pharm Date: 2015-07-23